CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the completion of its public offerings of 6,900,000 shares of common stock, including 900,000 shares purchased by the underwriters pursuant to their over-allotment option, and $287.5 million aggregate principal amount of 4.75% convertible senior subordinated notes due 2013, including $37.5 million aggregate principal amount of notes purchased by the underwriters pursuant to their over-allotment option. The aggregate gross proceeds from the common stock offering and the note offering, before commissions and expenses, are approximately $405.8 million.
